Matinas BioPharma -11.7% on secondary offering

|About: Matinas BioPharma Holdings... (MTNB)|By:, SA News Editor

Matinas BioPharma (NYSEMKT:MTNB) has slipped 11.7% postmarket after launching a public offering of common stock.

The company is selling all shares involved.

Terms weren't disclosed but underwriters will get a 30-day option to buy up to an additional 15% of shares at the offering price.

Sole book-runner is BTIG.

Subscribe for full text news in your inbox